BR112022010228A2 - Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas - Google Patents
Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadasInfo
- Publication number
- BR112022010228A2 BR112022010228A2 BR112022010228A BR112022010228A BR112022010228A2 BR 112022010228 A2 BR112022010228 A2 BR 112022010228A2 BR 112022010228 A BR112022010228 A BR 112022010228A BR 112022010228 A BR112022010228 A BR 112022010228A BR 112022010228 A2 BR112022010228 A2 BR 112022010228A2
- Authority
- BR
- Brazil
- Prior art keywords
- increased safety
- safety characteristics
- attenuated live
- vaccines
- leishmania parasite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/10—Protozoa; Culture media therefor
- C12N1/105—Protozoal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
VACINAS DE PARASITA DE LEISHMANIA VIVA ATENUADA COM CARACTERÍSTICAS DE SEGURANÇA AUMENTADAS. A presente invenção refere-se a espécies de Leishmania modificadas e suas composições, tais como organismos vivos e atenuados, composições imunogênicas, vacinas, e composições farmacêuticas. São descritos ainda métodos relacionados a espécies de Leishmania modificadas, tais como métodos de produção e métodos de uso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962949080P | 2019-12-17 | 2019-12-17 | |
PCT/US2020/065745 WO2021127271A1 (en) | 2019-12-17 | 2020-12-17 | Live attenuated leishmania parasite vaccines with enhanced safety characteristics |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022010228A2 true BR112022010228A2 (pt) | 2022-09-06 |
Family
ID=74195109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022010228A BR112022010228A2 (pt) | 2019-12-17 | 2020-12-17 | Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230039456A1 (pt) |
BR (1) | BR112022010228A2 (pt) |
WO (1) | WO2021127271A1 (pt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113583876A (zh) * | 2021-08-02 | 2021-11-02 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | EYFP敲入到Et.Actin基因的鸡柔嫩艾美尔球虫虫株的制备 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6194388B1 (en) | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO1998052581A1 (en) | 1997-05-20 | 1998-11-26 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
WO2005021030A1 (en) * | 2003-08-29 | 2005-03-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Live attenuated leishmania vaccines |
FR2863272B1 (fr) * | 2003-11-19 | 2006-06-09 | Inst Rech Developpement Ird | Nouveaux moyens pour la prevention des leishmanioses |
US20050176144A1 (en) * | 2004-02-06 | 2005-08-11 | O'daly Jose A. | Culture media compositions free of fetal bovine serum |
FR2881752B1 (fr) * | 2005-02-10 | 2009-07-31 | Inst Rech Pour Le Dev I R D Et | Moyens pour l'obtention de promastigotes de leishmanies avirulents, promastigotes obtenus et leurs applications |
EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
US20170306306A1 (en) | 2014-10-24 | 2017-10-26 | Life Technologies Corporation | Compositions and Methods for Enhancing Homologous Recombination |
-
2020
- 2020-12-17 WO PCT/US2020/065745 patent/WO2021127271A1/en active Application Filing
- 2020-12-17 US US17/786,129 patent/US20230039456A1/en active Pending
- 2020-12-17 BR BR112022010228A patent/BR112022010228A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021127271A1 (en) | 2021-06-24 |
US20230039456A1 (en) | 2023-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018002920A1 (es) | Nuevos derivados de pirazolopirimidina | |
NI201900085A (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
UY37563A (es) | Aislados de bacillus y usos de los mismos | |
AU2015296298A8 (en) | Flagellin-based agents and uses including effective vaccination | |
UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
CO2020001927A2 (es) | Método de producción de composiciones farmacéuticas que comprende el virus chikungunya inmunogénico chikv-delta5nsp3 | |
MX2021010060A (es) | Produccion de virus en huevos aviares. | |
PH12019501359A1 (en) | Polymorphs | |
WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
CR20170335A (es) | Compuestos cíclicos sustituidos con un sistema de anillos condensados | |
JOP20200323A1 (ar) | طرق لتصنيع تركيبات الأحماض الأمينية | |
MX2017016896A (es) | Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos. | |
PH12019500989A1 (en) | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof | |
PH12016502001A1 (en) | Novel bacteriophage and composition comprising same | |
CO2019010062A2 (es) | Novedoso bacteriófago clo-pep-2 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens | |
BR112019008781A2 (pt) | poxvírus quiméricos sintéticos | |
EA201990128A1 (ru) | Культуры клеточных линий из растений, принадлежащих к роду harpagophytum | |
WO2016100615A3 (en) | Methods and composition for neutralization of influenza | |
BR112022010228A2 (pt) | Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas | |
DOP2018000209A (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
PH12019501173A1 (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
GB2568440A (en) | Modified factor H binding protein | |
PH12016502000B1 (en) | Novel bacteriophage and composition comprising same | |
PL406631A1 (pl) | Antygen, szczepionka przeciwko grypie, układ do wytwarzania szczepionki, sposób wytwarzania antygenu oraz zastosowanie antygenu określonego powyżej do wytwarzania szczepionki przeciwko grypie | |
CU20210061A7 (es) | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer |